Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Sponsors

Lead Sponsor: Children's Oncology Group

Collaborator: National Cancer Institute (NCI)

Source Children's Oncology Group
Brief Summary

This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

Detailed Description

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Existing NRSTS samples from the COG D9902/ARST0332 studies Sampling Method: Non-Probability Sample

OBJECTIVES:

I. To determine the frequency with which actionable mutations are found in archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry (MS) analysis of tumor-derived deoxyribonucleic acid (DNA).

OUTLINE:

Archived DNA tissue samples are analyzed for frequency of genetic mutations, including single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.

Overall Status Completed
Start Date May 2016
Completion Date May 2016
Primary Completion Date May 2016
Study Type Observational
Primary Outcome
Measure Time Frame
Frequency of individual mutated genes in patients with NRSTS Up to 1 month
Genetic changes that are most common and likely to have the greatest therapeutic impact Up to 1 month
Enrollment 70
Condition
Intervention

Intervention Type: Other

Intervention Name: laboratory biomarker analysis

Description: Correlative studies

Arm Group Label: Correlative studies

Eligibility

Sampling Method: Non-Probability Sample

Criteria:

Inclusion Criteria:

- Archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor-derived DNA

- Synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), soft tissue sarcoma not otherwise specified (NOS), or other less common pediatric NRSTS

- Formalin-fixed, paraffin-embedded (FFPE) tissue from patients enrolled on:

- COG-D9902 Soft Tissue Sarcoma (STS) Biology and Banking Protocol

- COG-ARST0332 A Risk-Based Treatment for Pediatric NRSTS Study

- See Disease Characteristics

Gender: All

Minimum Age: N/A

Maximum Age: 30 Years

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Steve Skapek, MD Principal Investigator Children's Oncology Group
Location
Facility: Children's Oncology Group
Location Countries

United States

Verification Date

May 2016

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Arm Group

Label: Correlative studies

Description: Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.

Study Design Info

Observational Model: Cohort

Time Perspective: Retrospective

Source: ClinicalTrials.gov